Cell cycle and cancer

Journal of the National Cancer Institute

Volumn 87, Issue 20, 1995, Pages 1499-1501

  Clurman, Bruce E ^a   Roberts, James M ^a  

^a FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASES;

ANIMAL; CELL CYCLE; CELL TRANSFORMATION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; NOTE;

ANIMAL; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASES; HUMAN; MUTATION; NEOPLASMS;

EID: 0029647651     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.20.1499     Document Type: Editorial

References (28)

1. Hunter T, Pines J, Cyclins C and cancer J: Cyclin D and CDK inhiBitors come of age [see comment citation in Medline]. Cell 1994; 79: 573-82.
2. Sherr C.J. MammalianGi eyelins.Cell 1993;73:1059-65.
3. Sherr C.J, Roberts J.M. Inhibitors of mammalian Gi eyclin-dependent kinases. Genes Dev 1995; 9: 1149-63.
4. Harper J.W, Adami G.R, Wei N, Keyomarsi K, Elledge S.J. The p2l Cdk-in- teracting protein Cipl is a potent inhibitor of Gi cyclin-dependent kinases. Cell 1993; 75: 805-16.
5. Xiong Y, Hannon G.J, Zhang H, Casso D, Kobayashi R, Beach D. p2l is a universal inhibitor of cyclin kinases [see comment citation in Medline]. Nature 1993; 366: 701-4.
6. Gu Y, Turck C.W, Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993; 366: 707-10.
7. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAFl, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
8. Polyak K, Lee M.H, Erdjument-Bromage H, Koff A, Roberts J.M, Tempst P, et al. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994: 78: 59-66.
9. Toyoshima H, Hunter T. p27, a novel inhibitor of Gi cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
10. Lee M.H, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain stmcture and tissue_distribution. Genes Dev 1995; 9: 639-49.
11. Matsuoka S, Edwards M.C, Bai C, Parker S, Zhang P, Baldini A, et al. p57KIP2, a structurally distinct member of the p21CIPl Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650-62.
12. Serrano M, Hannon G.J, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [sec comment eitation in Medline]. Nature 1993; 366: 704-7.
13. Hannon G.J, Beach D. pl5INK4B is a potential effector of TGF-beta-in- duced cell cycle arrest [see eomment citation in Medline]. Nature 1994;371:257-61.
14. Hirai H, Roussel M.E, Kato J.Y, Ashmun R.A, Sherr C.J. Novel 1NK4 proteins, pl9 and pi8, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-81.
15. Chan F.K, Zhang J, Cheng L, Shapiro D.N, Winoto A. Identification of human and mouse pi9, a novel CDK4 and CDK6 inhibitor with homology to pl6ink4. Mol Cell Biol 1995;15:2682-8.
16. Sheaff R.J, Roberts J.M. Tumor suppression. Lessons in pl6 from phylum Falconium. CurrBiol 1995: 5: 28-31.
17. Hartwell L.H, Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629-34.
18. Kamb A, Gruis N.A, Weaver-Feldhaus J, Liu O, Harshman K, Tavtigian S.V, et al. A cell cycle regulator potentially involved in genesis of many tumor types [see comment citations in Medline]. Science 1994; 264: 436-40.
19. Jen J, Harper J.W, Bigner S.H, Bigner D.D, Papadopoulos N, Markowitz S, et al. Deletion of pl6 and pl5 genes in brain tumors. Cancer Res 1994; 54: 6353-8.
20. Nishikawa R, Fumari F.B, Lin H, Arap W, Berger M.S, Cavenee W.K, et al. Loss of PI 61NK4 expression is frequent in high grade gliomas. Cancer Res 1994; 55: 1941-5.
21. Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, et al. MTSl/pl6/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-9.
22. Okuda T, Shurtleff S.A, Valentine M.B, Raimondi S.C, Head D.R, Behm F, et al. Frequent deletion of pl6INK4a/MTSl and pl5INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321-30.
23. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (pi6) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685-90.
24. Otsuki T, Clark H.M, Wellmann A, Jaffe E.S, Raffeld M. Involvement of CDKN2 (pl6INK4A/MTSl) and pl5INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995; 55: 1436-40.
25. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, et al. pl6 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657-63.
26. Lo K.W, Huang D.P, Lau K.M. pl6 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995;55:2039-43.
27. Cheng J.Q, Jhanwar S.C, Klein W.M, Bell D.W, Lee W.C, Altomare D.A, et al. pl6 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-51.
28. Orlów I, Lacombe L, Hannon G.J, Serrano M, Pellicer I, Dalbagni G, et al. Deletion of the pi 6 and pi 5 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524-9.